Protective effect of kidney by low dose of darbepoetin alfa in patients with chronic kidney disease

Protective effect of kidney by low dose of darbepoetin alfa in patients with chronic kidney disease - Protective effect of kidney by low dose of darbepoetin alfa in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008984

Enrollment

Registered

2012-09-30

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disaese

Interventions

darbepoetin alfa Only iron supplementation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic kidney disease(eGFR15-60ml/min),with renal anemia(hemoglobin concentration 9-11g/dl),and has never been administered in the past the formulation ESA. Patients with above conditions are met, consent was obtained from the person with sufficient explanation.

Exclusion criteria

Exclusion criteria: Excluded patients with hypertension uncontrolled, congestive heart failure, surgery with massive bleeding within 16 weeks, blood disorders and malignancies, with patients treated with Doosan Mepichiosutan Henin and anabolic hormone and testosterone within 16 weeks, drug allergy, collagen disease and vasculitis, and patients who received a blood transfusion within 16 weeks.

Design outcomes

Primary

Measure	Time frame
Differences in rate of decline of eGFR at the time of 6 months in the treatment groups and the non-treated group of darbepoetin	—

Secondary

Measure	Time frame
Changes in serum creatinine, urine protein content, NAG, the concentration of Hemoglobin	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026